The blockbuster weight-loss drugs Ozempic and Wegovy may do more than trim waistlines and control blood sugar. A new clinical trial suggests their active ingredient, semaglutide, can also slow biological aging.
Published in Nature Communications, the study offers the first randomized, placebo-controlled evidence in humans that a GLP-1 receptor agonist may influence how quickly the body ages at a molecular level.
Semaglutide Slowed Epigenetic Aging Clocks
Researchers at the University of California San Diego and collaborating institutions analyzed data from an earlier trial involving 108 adults living with HIV. All participants had HIV-associated lipohypertrophy, a condition that causes excess fat buildup around the abdomen. Roughly half received weekly semaglutide injections; the other half received a placebo.
The team measured biological age using several epigenetic clocks. These tools estimate aging by tracking DNA methylation, chemical tags that switch genes on or off without altering the DNA sequence. People with HIV often experience accelerated biological aging, even when the virus is well controlled with antiretroviral therapy.
Compared with the placebo group, those on semaglutide showed slower biological aging across multiple epigenetic clocks tied to inflammation and the health of the blood, brain, heart, kidneys, liver, and metabolism. One clock, DunedinPACE, indicated a 9% slower pace of biological aging. Another, PCGrimAge, showed a significant slowing of processes linked to age-related disease and all-cause mortality risk.
Why GLP-1 Drugs May Influence Aging
Semaglutide belongs to a class of drugs called GLP-1 receptor agonists. These medications reduce inflammation and improve metabolic health. Chronic inflammation and metabolic dysfunction are known drivers of biological aging. By calming those processes and reducing excess fat, semaglutide may postpone several molecular signs of aging.
The study focused on adults with HIV, a population that tends to age faster biologically. But the mechanisms at play, inflammation and metabolic stress, are not unique to that group. The findings suggest the drug could have broader anti-aging effects.
What This Means Going Forward
First author Michael Corley, PhD, an associate professor at UC San Diego School of Medicine, noted that the results are encouraging but preliminary. The trial was small, and the participants all had HIV. Larger, more diverse studies are needed before anyone can conclude that semaglutide helps people age more slowly across the general population.
The study does not claim that Ozempic or Wegovy are anti-aging drugs. It provides the first clinical evidence that a GLP-1 medication may influence human aging at the epigenetic level. That opens a new line of inquiry for researchers exploring how existing drugs might delay age-related diseases.
